{
  "ticker": "JNJ",
  "target_date": "2025-03-07",
  "actual_date": "2025-03-07",
  "collected_at": "2025-12-08T11:29:28.201762",
  "price": {
    "open": 161.51,
    "high": 164.76,
    "low": 161.09,
    "close": 163.03370666503906,
    "volume": 9637600,
    "change_1d_pct": 0.52,
    "change_7d_pct": 2.21,
    "change_30d_pct": 14.58
  },
  "technicals": {
    "rsi_14": 76.63,
    "sma_20": 157.06,
    "sma_50": 148.62,
    "macd": 4.164,
    "macd_signal": 4.027,
    "macd_histogram": 0.137,
    "bb_upper": 167.42,
    "bb_lower": 146.7,
    "price_vs_sma20_pct": 3.8,
    "price_vs_sma50_pct": 9.7,
    "volume_ratio": 1.04
  },
  "fundamentals": {
    "market_cap": 488665284608,
    "pe_ratio": 19.577703,
    "forward_pe": 19.134434,
    "price_to_book": 6.1560993,
    "price_to_sales": 5.302991,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.4,
    "pct_from_52w_low": 44.17
  },
  "macro": {
    "spy": {
      "price": 570.92,
      "change_1d_pct": 0.56,
      "change_7d_pct": -1.56
    },
    "vix": {
      "level": 23.37,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.32
    },
    "dollar_index": {
      "level": 103.84
    },
    "gold": {
      "price": 2904.7
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson Statement on VENTURA Program",
      "source": "Finnhub",
      "datetime": 1741344740,
      "summary": "TITUSVILLE, N.J- Johnson & Johnson has made the decision to discontinue the Phase 3 VENTURA development program evaluating aticaprant as an adjunctive treatment for major depressive disorder due to...",
      "url": "https://finnhub.io/api/news?id=0038d3ee60d653c1a5149ca8ea5000fb6b4f7bdb7693144cd264bfe944fbe372"
    },
    {
      "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
      "source": "SeekingAlpha",
      "datetime": 1741340054,
      "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
      "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139"
    },
    {
      "headline": "Finance Executives Seek Stability Amid Erratic Tariff Shifts",
      "source": "DowJones",
      "datetime": 1741291200,
      "summary": "Finance Executives Seek Stability Amid Erratic Tariff Shifts",
      "url": "https://finnhub.io/api/news?id=44fa51dedfeeede4a0d0dff6ea8a8f2f5a43144122b8c89b89f2629a41f778ce"
    },
    {
      "headline": "J&J to stop studies of depression drug due to low effectiveness",
      "source": "Finnhub",
      "datetime": 1741281983,
      "summary": "Johnson & Johnson will stoplate-stage studies of its experimental drug to treat majordepressive disorder due to a lack of sufficient efficacy, thedrug and medical device maker said on Thursday. ...",
      "url": "https://finnhub.io/api/news?id=480cca577bdf41789a0d937db53862bb4f300ee404f4dee673f51f761a29f78a"
    },
    {
      "headline": "10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil",
      "source": "SeekingAlpha",
      "datetime": 1741244400,
      "summary": "The trade war is causing market volatility. Read more about low-volatility dividend aristocrats offering stability in volatile markets.",
      "url": "https://finnhub.io/api/news?id=1df44ae7a302f8aa5a896c0a4ec607bb91acd23603607d427fbbe66a5a760129"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297319.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000095/xslF345X05/wk-form4_1741297319.xml"
    },
    {
      "form": "4",
      "date": "2025-03-06",
      "description": "xslF345X05/wk-form4_1741297124.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000093/xslF345X05/wk-form4_1741297124.xml"
    },
    {
      "form": "4",
      "date": "2025-02-26",
      "description": "xslF345X05/wk-form4_1740613359.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000086/xslF345X05/wk-form4_1740613359.xml"
    },
    {
      "form": "8-K",
      "date": "2025-02-26",
      "description": "d863514d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525036773/d863514d8k.htm"
    },
    {
      "form": "8-K",
      "date": "2025-02-20",
      "description": "d866332d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525030851/d866332d8k.htm"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}